CollPlant, developer of plant-based rhCollagen technology for tissue repair, will be expanding its research into bioprinting organs and other tissues.
Research into collagen-based bioinks will be the focus of a
new division established by CollPlant (Israel). The inks are intended to be
utilized in the production of 3D printed organs and other tissues. CollPlant’s proprietary
rhCollagen technology utilizes genetically engineered tobacco plants to grow collagen tissues identical to the type I collagen produced by the human
body. It is hoped this artificial collagecould offer a solution to tissue regeneration and repair.